Krystal Biotech, Inc.
In the published model solve dated 2026-Q2, anchored at $347.00, Krystal Biotech, Inc. (KRYS) is priced for today's economics sustained for ~13.1 years. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The narrative was composed June 27, 2026 from SEC EDGAR filings.
• Krystal is the rare biotech that is already profitable, selling Vyjuvek, an approved gene therapy for a rare skin disease, at a 95% gross margin and funding a deep pipeline out of its own cash rather than dilutive raises [Source: Krystal Q1 2026 results, May 2026]. • The price is the issue, not the business: at roughly 57 times operating income it embeds something like fourteen years of ceiling-rate growth, a durability bet only a small fraction of fast-growers have ever delivered. • Watch the
Is KRYS overvalued? See what's priced in →
352 institutional managers reported holding KRYS in 13F filings for the quarter ended 2026-03-31. Together they hold about 92% of the company; the top 10 hold 63%. 65 opened new positions that quarter. Held by FMR (Fidelity), BlackRock, Vanguard Group, among others. On the short side, 3.1M shares were sold short as of the 2026-06-15 count, about 10% of shares outstanding (10.9 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
KRYS's share count grew 31.9% over the past five years. It pays no dividend.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
No open-market insider buys on file at KRYS over the trailing three years. Absence is a fact about the company, not a signal. 7 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
KRYS's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2022-08-09 | -5.2% | -17.8% |
| 2023-02-28 | +4.4% | +1.1% |
| 2023-11-07 | -10.7% | +18.3% |
| 2024-05-07 | +0.4% | +19.7% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
KRYS's latest 8-K filings: 2026-08-03 (items 2.02, 9.01); 2026-07-21 (items 8.01, 9.01); 2026-05-20 (items 5.07); 2026-05-04 (items 9.01); 2026-02-17 (items 2.02).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: June 27, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.